Thus, for patients who develop irBP as a side effect of cancer immunotherapy, IL-4 and IL-13 inhibitors such as dupilumab, so far approved to treat atopic dermatitis and prurigo nodularis, appear to be a promising new treatment option. The gene discussed is IL4; the disease is atopic eczema.